introduction: influenza a virus causes unpredictable epidemics and pandemics by creating antigenic variations. with the appearance of each new strain, rapid emergency countermeasures are taken against this new strain. hence, designing an applicable and cross protective strategy to counter this virus is of great importance. to achieve this, choosing conserved antigenic regions in influenza virus...

A potential target for the development of universal vaccine strategies against Influenza A is the M2 protein - a membrane protein with a highly conserved extracellular domain. In this study we developed engineered T-cell receptors, by fusing M2-specific antibody sequences with T-cell receptor transmembrane and signaling domains to target influenza infected cells. When expressed on T-cells, thes...

Current therapeutic options for the treatment of influenza virus infections are limited. Only 2 classes of agents have licensed products, neuraminidase (NA) inhibitors and M2 inhibitors, and only NA inhibitors are active against currently circulating seasonal viruses. While observational studies show a benefit of NA inhibitor treatment for hospitalized patients with influenza [1], optimal treat...

Currently licensed vaccines against the influenza A virus (IAV) need to be updated annually to match the constantly evolving antigenicity of the influenza virus glycoproteins, hemagglutinin (HA), and neuramidiase (NA). Attempts to develop universal vaccines that provide broad protection have resulted in some success. Herein, we have shown that a replication-deficient adenovirus expressing H5/M2...